Multiple Sclerosis Clinical Trial
Official title:
Immunoregulation by Controlled Parasite Exposure in Multiple Sclerosis.
The aim of the study is to determine whether controlled infection with a clinically safe number of larvae of hookworm results in an immune response that is protective in relapsing MS.
Studies have shown that there may be an inverse relationship between infections with worms
including hookworms and inflammatory diseases including multiple sclerosis (MS). This has
been explained by a protective immune reaction that is triggered by the hookworm in the body
that dampens inflammation. In mice with MS, infections with some mouse worms reduced the
inflammation and damage to their brain. The primary purpose of this study is to determine
whether people with MS who are exposed to a small number of hookworms will develop this
protective immune reaction that may reduce MS disease activity. We also plan to determine
the effect of the hookworms on relapses during 1 year study.
A study of people with MS naturally infected with intestinal parasites did show significant
protection over 5 years, and the levels of biological markers of the infection and some
immune substances triggered by it were similar to the ones we obtained with controlled
infection in normal volunteers, allergic and asthmatic peoples. We think the study has a
genuine potential to benefit people with MS, and there is known interest in the MS patient
community. At the therapeutic doses proposed here, this is an innocuous infection. Natural
hookworm infection affects 1 billion people worldwide, often without symptoms unless the
parasite load is very high. Our controlled exposure studies have shown good tolerability and
safety; the risk of infecting others and auto-infection virtually is nil in Western standard
hygiene conditions. Many people with MS when asked stated they would prefer an innocuous
infection with microscopic larvae to a man-made product that may have more side effects. If
the protective mechanisms are determined these studies may also lead to new ways of treating
MS, possibly by selecting only the specific chemical components of the worms and the immune
response to them that confer protection.
The increase in MS in the Western world, along with other autoimmune inflammatory diseases
and asthma may be attributed to decreased exposure to infections such as gut parasites due
to improved hygiene ('the hygiene hypothesis'). In animal models, controlled parasite
infections including hookworms and related worms protect against MS-like disease. Parasites
have evolved host-specific molecular mechanisms to dampen or condition the excessive immune
responses against them and thus survive. These parasites induce regulatory mechanisms
including Treg and a novel class of B cells that also dampen immune responses called Breg
and were recently shown to improve MS in natural infection. They may suppress a class of
lymphocytes that cause most damage in MS, Th17 cells. We will produce, with controlled
exposure, a similar response to those associated with protective natural exposure in MS. We
have the unique combination of expertise in hookworm biology, controlled parasite exposure
and immunology of MS and MS trials and our data from our other human studies indicate this
is a safe and tolerable intervention of significant potential.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
| Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
| Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
| Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
| Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
| Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
| Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
| Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
| Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
| Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
| Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
| Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
| Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
| Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
| Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
| Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
| Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
| Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
| Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
| Completed |
NCT02845635 -
MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis
|